GHK-Cu and ipamorelin for MCAS and Lyme disease: what the evidence shows

What did @beeaaaykay actually say?

The creator described a cautious, self-directed peptide protocol using GHK-Cu (copper peptides) and ipamorelin, starting at "three units each" in an insulin syringe on separate days. They attributed this slow approach to a history of undiagnosed Lyme disease and subsequent Mast Cell Activation Syndrome (MCAS), which left them reactive to foods, medications, and chemicals. They reported a headache initially, skin irritation from GHK-Cu, and used a TikTok recommendation to increase vitamin C intake to address that irritation. They say they're still on low doses but plan to increase.

To be clear: this is a personal health update, not medical advice. But 1.9K viewers are watching it as a reference point, so the claims are worth examining carefully.

Does the science back this up?

The general logic of low-and-slow dosing in mast cell disorders has real clinical support. The specific peptide claims are a different story. GHK-Cu has legitimate research behind it, mostly in wound healing and anti-inflammatory contexts. Ipamorelin is a growth hormone secretagogue with far thinner human trial data.

On MCAS specifically: the condition involves dysregulated mast cell degranulation triggered by a wide range of stimuli, including peptides and injectable substances. A cautious introduction protocol is consistent with how some clinicians approach novel compounds in reactive patients. However, there are no published clinical trials on GHK-Cu or ipamorelin in MCAS populations. The creator is extrapolating general tolerance-building logic onto a specific condition without that evidence base.

GHK-Cu has been studied for skin repair and inflammation modulation. Pickart and Margolina (2018, Cosmetics) reviewed its role in tissue remodeling and noted anti-inflammatory signaling activity. Whether that translates to systemic subcutaneous use at "three units" is completely unestablished.

The vitamin C recommendation for copper peptide skin irritation has no peer-reviewed basis the research team could locate. It may be harmless, but it came from a TikTok comment, not a clinician.

What did they get wrong (or right)?

Credit where it is due: starting with a very low test dose before committing to a full protocol is genuinely sensible for someone with a reactive immune system. That is not just bro-science. It reflects a real clinical principle used in allergen desensitization and drug challenges.

What they got wrong, or at least did not address: ipamorelin stimulates growth hormone release through the ghrelin receptor. In patients with mast cell disorders, ghrelin receptor agonism has shown mixed results on mast cell activity. Klooker et al. (2010, Gut) found ghrelin signaling can modulate gut mast cell responses, meaning ipamorelin is not immunologically inert in this population. The creator treats it as neutral, which it may not be.

Calling the compound "epimorline" throughout also suggests they are working from second-hand information rather than primary sources, a minor point, but worth flagging for viewers who might search for the wrong compound.

The vitamin C tip for GHK-Cu skin irritation is unverified advice passed through social media. Skin irritation from subcutaneous GHK-Cu injections is more plausibly related to pH, excipient content, or injection technique, none of which vitamin C would address.

What should you actually know?

MCAS is a real, underdiagnosed condition, and the creator deserves credit for naming it accurately. But MCAS patients are among the highest-risk groups for novel compound reactions precisely because their mast cells degranulate unpredictably. Headaches and skin irritation, which the creator reported and then rationalized away, can be early mast cell mediator release symptoms, not just adjustment effects.

Neither GHK-Cu nor ipamorelin is FDA-approved for therapeutic use. Both exist in a compounded gray market where purity, peptide concentration, and excipient content vary significantly between suppliers. Trontelj et al. (2022, Pharmaceuticals) analyzed compounded peptide quality and found substantial batch-to-batch variability in unregulated preparations, which matters a lot for a population that reacts to excipients.

Anyone with MCAS considering peptide therapy should be doing this with a physician who can monitor mast cell mediator levels, not based on insulin syringe unit counts shared on TikTok. The low-dose logic is sound in principle. The execution without clinical supervision is not.

The bottom line

The creator's instinct to go slow is correct. The framing that GHK-Cu and ipamorelin are well-suited for MCAS recovery is getting ahead of the evidence by years, possibly decades. The vitamin C skin irritation fix came from a comment section, not a dermatologist. And the plan to "amp" dosing without clinical guidance in a patient with documented immune reactivity is exactly the kind of escalation that should happen under supervision, not on a TikTok timeline.